Print

Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans  
10/23/2012 9:05:56 AM

NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced a presentation on SP-333, the company's second investigational drug from the guanylate cyclase-C agonist class, at the American College of Gastroenterology 77th annual meeting, which is being held in Las Vegas, NV from October 19-24, 2012. The presentation highlights pioneering research demonstrating that SP-333 ameliorates colitis in mice through inhibition of NF-kappa B activation. SP-333 recently entered clinical trials as an experimental drug for the treatment of ulcerative colitis, and is presently in a Phase I trial in healthy volunteers.
//-->